Canada’s MedC to Develop Cannabis-Based Cancer Treatment Based on Israeli Technology
MedC previously invested in the development of the treatments at Israel’s agricultural research organization, Volcani Center
MedC, founded by Israeli brothers Avi and Guy Drori, also announced a partnership with a subsidiary of Israel-based Nextar Chempharma Solutions, an outsourcing company for drug development and manufacturing services, to develop treatments.
Volcani Center is preparing to submit the patents for the treatment of Cutaneous T cell lymphoma (CTCL), a type of immune system cancer that is classified by the U.S. Food and Drug Administration as an orphan disease. Clinical trials are planned for the beginning of 2019.